JY
CCCC icon

Jeff Yass’s C4 Therapeutics CCCC Stock Holding History

Jeff Yass’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Buy
+38,300
New +$131K ﹤0.01% 12055
2026
Q1 		– Sell
-37,100
Closed -$70.9K – 13232
2025
Q4 		$70.9K Sell
37,100
-94,300
-72% -$223K ﹤0.01% 11624
2025
Q3 		$292K Buy
+131,400
New +$315K ﹤0.01% 10172
2024
Q4 		– Sell
-36,100
Closed -$206K – 12258
2024
Q3 		$206K Hold
36,100
– – ﹤0.01% 10421
2024
Q2 		$167K Sell
36,100
-221,700
-86% -$1.32M ﹤0.01% 10585
2024
Q1 		$2.11M Sell
257,800
-249,900
-49% -$1.94M ﹤0.01% 5214
2023
Q4 		$2.87M Buy
+507,700
New +$1.16M ﹤0.01% 4660
2022
Q2 		– Sell
-32,400
Closed -$786K – 12961
2022
Q1 		$786K Buy
+32,400
New +$787K ﹤0.01% 7766

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's CCCC Position: Q2 2026 in Review

Jeff Yass increased its C4 Therapeutics (CCCC) stake by 35% in Q2 2026, buying an estimated $1.52M and bringing the position to 1,732,210 shares worth $8.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

Jeff Yass first reported a position in CCCC in Q1 2021 and has held it in 21 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Jeff Yass held 1,732,210 shares of C4 Therapeutics worth $8.09M as of Q2 2026.
  • Jeff Yass bought 445,370 C4 Therapeutics shares in Q2 2026, an estimated $1.52M.
  • C4 Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3734 holding.
  • Jeff Yass first reported a position in C4 Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.